Metformin for Antipsychotic-Related Weight Gain and Metabolic Abnormalities: When, for Whom, and for How Long?

Dr. Correll has served as a consultant and/or advisor to and has received honoraria from Actelion, Alexza, the American Academy of Child and Adolescent Psychiatry, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Lundbeck, Medavante, Medscape, Merck, NIMH, Janssen/Johnson and Johnson, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda; and he has received grant support and/or donation of medication from Bristol-Myers Squibb, the Feinstein Institute for Medical Research, Janssen/Johnson and Johnson, and NIMH. Dr. Sikich has received research grant support from or has participated in clinical trials sponsored by Autism Speaks, Bristol-Myers Squibb, Curemark, Forest, Foundation of Hope, Merck, NIMH, Otsuka Research Institute, Seaside Pharmaceuticals, Sunovion, and SynapDx; she has served as a consultant to ABT Associates and Sanofi-Aventis and has received software for a computer intervention in schizophrenia from Posit Science; she also serves on the data safety and monitoring boards for the National Institute of Child Health and Human Development Rare Diseases Network and the Research Foundation for Mental Hygiene. Dr. Riddle has received research grant support from NIMH and a donation of medication from Bristol-Myers Squibb and serves on the data safety and monitoring boards for the Best Pharmaceuticals for Children Act. Dr. Reeves has received research grant support from NIMH and a donation of medication from Bristol-Myers Squibb. Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships.